跳至主要内容
临床试验/CTRI/2017/08/009526
CTRI/2017/08/009526尚未招募未知

Comparison of TARE vs TACE in the management of intermediate Hepatocellular Carcinoma (TASIHCC): A Randomized Control Trial - TASIHCC

Department of Gastroenterology AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Written informed consent provided
  • 2.Aged >=18 years
  • 3.AASLD criteria for diagnosis of HCC.
  • 4.BCLC stage A and B.
  • 5.ECOG performance status 0
  • 6.Hemoglobin >= 9 g/dl, neutrophils >=1,500/mm3 and platelets >=50,000/mm3
  • 7.Normal kidney function tests: Serum creatinine < 1.0 mg/dl
  • 8.Bilirubin <= 1mg/dl, AST or ALT <= 5 x ULN (ULN: 40 IU/L), INR <= 1.5
  • 9.Child-Pugh class A-B

排除标准

  • 1.Extra hepatic metastases
  • 2.Previously treated HCC
  • 3.Advanced liver disease with a Child-Pugh score C or active gastrointestinal bleeding or encephalopathy or refractory ascites
  • 4.Pregnant or breastfeeding women
  • 5.Allergy to contrast agents
  • 6.Contraindication to hepatic artery catheterization, such as severe peripheral arterial disease precluding catheterization
  • 7.Mental illness or other psychological disorder affecting the informed consent
  • 8.Patient unable or unwilling to comply with the treatment and follow-up required by the study
  • 9.Unable to take oral medication

研究者

发起方
Department of Gastroenterology AIIMS New Delhi

相似试验